Aurobindo Pharma Ltd
Company Profile
Business description
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.
Contact
Plot No. 1, Survey No. 83/1
Galaxy, Floors 22-24
Hyderabad Knowledge City
Raidurg Panmaktha, Ranga Reddy District
HyderabadTG500032
INDT: +91 4066725000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
40,750
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
stocks
Avoid this overvalued ASX lithium producer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,424.08 | 38.59 | 0.46% |
| DAX 40 | 24,883.52 | 143.16 | 0.58% |
| Dow JONES (US) | 52,086.83 | 237.93 | 0.46% |
| FTSE 100 | 10,529.69 | 68.06 | 0.65% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,276.66 | 199.98 | -0.78% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,348.00 | 10.22 | -0.14% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |